Optimal first line therapy for rare kidney cancer variants (non-clear cell):  Immunotherapy

Optimal first line therapy for rare kidney cancer variants (non-clear cell):  Immunotherapy

User Photo
kidneycancer

1 year
13 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Primo N. Lara, Jr., MD Director, UC Davis Comprehensive Cancer Center Professor of Medicine and Executive Associate Dean UC Davis School of Medicine at the Kidney Cancer Association International Meeting, Miami FL
November 15, 2019
Up Next Autoplay
>